# SpyGlass Pharma, Inc.: financial statements, quarterly

SGP · Nasdaq · CIK 1778922 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sgp.md) · [Financials](/companies/sgp/financials.md) · [Filings](/companies/sgp/filings.md) · [Insiders](/companies/sgp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sgp/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development | $m | [6.1](/filings/0001778922-26-000035.md) | [7.3](/filings/0001778922-26-000045.md) | [8.5](/filings/0001778922-26-000035.md) | [10.9](/filings/0001778922-26-000045.md) |
| Operating income | $m | [(7.4)](/filings/0001778922-26-000035.md) | [(9.3)](/filings/0001778922-26-000045.md) | [(15.4)](/filings/0001778922-26-000035.md) | [(22.0)](/filings/0001778922-26-000045.md) |
| Income tax | $m | [0.0](/filings/0001778922-26-000035.md) | [0.0](/filings/0001778922-26-000045.md) | [0.0](/filings/0001778922-26-000035.md) | [0.0](/filings/0001778922-26-000045.md) |
| Net income | $m | [(8.8)](/filings/0001778922-26-000045.md) | [(8.7)](/filings/0001778922-26-000045.md) | [(13.8)](/filings/0001778922-26-000045.md) | [(19.9)](/filings/0001778922-26-000045.md) |
| Diluted EPS | $ per share | [(3.96)](/filings/0001778922-26-000035.md) | [(3.81)](/filings/0001778922-26-000045.md) | [(0.69)](/filings/0001778922-26-000035.md) | [(0.59)](/filings/0001778922-26-000045.md) |
| Basic EPS | $ per share | [(3.96)](/filings/0001778922-26-000035.md) | [(3.81)](/filings/0001778922-26-000045.md) | [(0.69)](/filings/0001778922-26-000035.md) | [(0.59)](/filings/0001778922-26-000045.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [16.3](/filings/0001778922-26-000020.md) | not reported | not reported | [96.4](/filings/0001778922-26-000045.md) | [239](/filings/0001778922-26-000035.md) | [223](/filings/0001778922-26-000045.md) |
| Current assets | $m | not reported | [17.4](/filings/0001778922-26-000020.md) | not reported | not reported | [109](/filings/0001778922-26-000045.md) | [253](/filings/0001778922-26-000035.md) | [236](/filings/0001778922-26-000045.md) |
| Total assets | $m | not reported | [23.3](/filings/0001778922-26-000020.md) | not reported | not reported | [116](/filings/0001778922-26-000045.md) | [258](/filings/0001778922-26-000035.md) | [243](/filings/0001778922-26-000045.md) |
| Current liabilities | $m | not reported | [7.8](/filings/0001778922-26-000020.md) | not reported | not reported | [8.6](/filings/0001778922-26-000045.md) | [6.7](/filings/0001778922-26-000035.md) | [9.4](/filings/0001778922-26-000045.md) |
| Total liabilities | $m | not reported | [11.2](/filings/0001778922-26-000020.md) | not reported | not reported | [10.2](/filings/0001778922-26-000045.md) | [8.3](/filings/0001778922-26-000035.md) | [11.1](/filings/0001778922-26-000045.md) |
| Shareholders' equity | $m | [(33.0)](/filings/0001778922-26-000020.md) | [(60.5)](/filings/0001778922-26-000045.md) | [(68.9)](/filings/0001778922-26-000045.md) | [(78.4)](/filings/0001778922-26-000045.md) | [(98.8)](/filings/0001778922-26-000045.md) | [250](/filings/0001778922-26-000045.md) | [232](/filings/0001778922-26-000045.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.2)](/filings/0001778922-26-000035.md) | [(6.3) d](/filings/0001778922-26-000045.md) | [(13.5)](/filings/0001778922-26-000035.md) | [(14.8) d](/filings/0001778922-26-000045.md) |
| Capital expenditure | $m | [0.2](/filings/0001778922-26-000035.md) | [0.1 d](/filings/0001778922-26-000045.md) | [0.7](/filings/0001778922-26-000035.md) | [1.9 d](/filings/0001778922-26-000045.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.2](/filings/0001778922-26-000035.md) | [2.3](/filings/0001778922-26-000045.md) | [19.9](/filings/0001778922-26-000035.md) | [33.4](/filings/0001778922-26-000045.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 33,447,979 at 2026-07-29, from the cover of the [10-Q filed 2026-08-06](/filings/0001778922-26-000045.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.